Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valeant Plans Sales Rep Increase, DTC Campaign For Jublia

This article was originally published in The Pink Sheet Daily

Executive Summary

Valeant has something to prove with the launch of Jublia, a topical treatment for toenail fungus, which it has held up as an example of its R&D strategy at work.

You may also be interested in...



Deal Watch: Pfizer Invests In Spero, Parexel Trades Hands

EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.

Novartis Poised To Face Off With AstraZeneca In PNH After Second Iptacopan Trial

The Phase III APPOINT-PNH study, testing iptacopan in treatment-naïve PNH patients, met its primary endpoint, positioning the oral drug as a potential new competitor to Soliris and Ultomiris.

Prometheus Phase II Data For Novel TL1A Inhibitor Impresses On Efficacy

The company plans to move PRA023 forward into Phase III studies based on positive Phase II safety and efficacy data in UC and Crohn's disease, positioning Prometheus in a race with Roivant.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel